CADRENAL THERAPEUTICS INC
CVKD · NASDAQ
Updated at 2026-10-13 15:28:33
- Today's High
- $0.98
- Today’s Low
- $0.87
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $0.91
- Previous Close
- $0.87
- Volume
- 111.63K
- Market Cap
- $3.11M
- P/E Ratio
- --
- EPS
- $-4.92
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Pharmaceuticals
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 822 A1A NORTH, PONTE VEDRA, FL, UNITED STATES, 32082
- Country
- US
- Listing Date
- 2023-01-20
- Fiscal Year End
- December
- Shares Outstanding
- 3.1M
- CIK
- 0001937993
- Website
- www.cadrenal.com
Cadrenal Therapeutics, Inc. (CVKD) is a clinical-stage biopharmaceutical firm dedicated to developing groundbreaking therapies for renal diseases and associated disorders. Leveraging its proprietary drug platforms, the company is advancing a strong pipeline aimed at fulfilling significant unmet medical needs within renal health. With a focus on scientific innovation and a commitment to patient-centered solutions, Cadrenal is strategically positioned for transformative contributions to patient care, highlighting its substantial growth potential in the dynamic biopharmaceutical sector.
Financial Metrics
Revenue
2026-06-30
$0
2026-03-31
$0
2025-12-31
$0
2025-09-30
$0
Operating Expenses
2026-06-30
$3.34M
2026-03-31
$2.51M
2025-12-31
$3.06M
2025-09-30
$2.73M
Net Income
2026-06-30
-$3.32M
2026-03-31
-$2.49M
2025-12-31
-$3.03M
2025-09-30
-$2.68M
Net Profit Margin
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
Earnings Per Share
2026-06-30
$-1.14
2026-03-31
$-1.04
2025-12-31
$-1.41
2025-09-30
$-1.31
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$3.33M
2026-03-31
-$2.49M
2025-12-31
-$3.03M
2025-09-30
-$2.68M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Expenses | $3.34M | $2.51M | $3.06M | $2.73M |
| Net Income | -$3.32M | -$2.49M | -$3.03M | -$2.68M |
| Net Profit Margin | -- | -- | -- | -- |
| Earnings Per Share | $-1.14 | $-1.04 | $-1.41 | $-1.31 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$3.33M | -$2.49M | -$3.03M | -$2.68M |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.